BlackRock’s BridgeBio Oncology BBOT Stock Holding History

BlackRock’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.4M	Buy	4,009,791 +1,855,751	+86%	+$14.4M	﹤0.01%	3358
2026 Q2	$16.4M	Buy	2,154,040 +65,743	+3%	+$549K	﹤0.01%	3396
2026 Q1	$18.7M	Buy	2,088,297 +3,460	+0.2%	+$37.2K	﹤0.01%	3127
2025 Q4	$26.1M	Buy	2,084,837 +36,285	+2%	+$440K	﹤0.01%	2940
2025 Q3	$23.7M	Buy	2,048,552 +549,687	+37%	+$5.73M	﹤0.01%	2988
2025 Q2	$15.9M	Hold	1,498,865	–	–	﹤0.01%	3158
2025 Q1	$16.9M	Hold	1,498,865	–	–	﹤0.01%	3041
2024 Q4	$15.7M	Sell	1,498,865 -1,135	-0.1%	-$11.9K	﹤0.01%	3190
2024 Q3	$15.7M	Hold	1,500,000	–	–	﹤0.01%	3181
2024 Q2	$15.3M	Hold	1,500,000	–	–	﹤0.01%	3141
2024 Q1	$15.6M	Buy	+1,500,000	New	+$15.5M	﹤0.01%	3131

Other funds holding BBOT

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

BlackRock's BBOT Position: Q3 2026 in Review

BlackRock increased its BridgeBio Oncology (BBOT) stake by 86% in Q3 2026, buying an estimated $14.4M and bringing the position to 4,009,791 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3358.

BlackRock first reported a position in BBOT in Q1 2024 and has held it in 11 quarters since. The position peaked at $26.1M in Q4 2025. 44 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.

BlackRock held 4,009,791 shares of BridgeBio Oncology worth $16.4M as of Q3 2026.
BlackRock bought 1,855,751 BridgeBio Oncology shares in Q3 2026, an estimated $14.4M.
BridgeBio Oncology made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #3358 holding.
BlackRock first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 11 quarters since.
BlackRock's BridgeBio Oncology position peaked at $26.1M in Q4 2025.
44 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.